NanoViricides (NYSE-A:NNVC) is positioning itself for a pivotal year in 2025, with plans to advance its lead antiviral candidate, NV-387, into multiple Phase II clinical trials.
The company is planning to accelerate its development pipeline, focusing on MPox treatment in Central Africa, viral acute respiratory infections, and a potential pediatric RSV indication.
Having successfully completed a Phase Ia/Ib clinical trial in late 2023, NV-387 showed no adverse effects, clearing the way for further clinical development.
NanoViricides has now engaged a Clinical Research Organization (CRO) to oversee the Phase II trial for MPox, with trial sites identified in two African countries.
Beyond MPox, the company is preparing to launch a Phase II trial for NV-387 in viral acute respiratory infections, an area with significant global demand. Additionally, NanoViricides is working toward a pre-Investigational New Drug (pre-IND) filing with the FDA for an RSV indication, targeting an unmet need in pediatric patients.
The company’s financial position remains a focus, with approximately $7.5 million in available funding as of early 2025, sourced from an at-the-market offering and a $3 million credit line. NanoViricides acknowledged that additional capital will be required to sustain operations through 2026 and to fully execute its clinical plans.
Another key priority for the year is preparing NV-387 as a countermeasure against the emerging H5N1 bird flu threat. Given the virus’s rapid mutation and limitations in current vaccines, NanoViricides sees an opportunity for its broad-spectrum antiviral to play a role in pandemic preparedness.